Metastatic disease is the leading cause of cancer mortality. Identifying biomarkers and regulatory mechanisms is important toward developing diagnostic and therapeutic tools against metastatic cancer. In this study, we demonstrated that podocalyxin-like 1 (PODXL) is overexpressed in breast tumor cells and increased in lymph node metastatic cancer. Mechanistically, we found that the expression of PODXL was associated with cell motility and invasiveness. Suppression of PODXL in MDA-MB-231 cells reduced lamellipodia formation and focal adhesion kinase (FAK) and paxillin phosphorylation. PODXL knockdown reduced the formation of invadopodia, such as inhibiting the colocalization of F.-actin with cortactin and suppressing phosphorylation of corta...
The advent of targeted therapies has vastly improved cancer diagnostics and treatments over the last...
Colon cancer is the third most common cancer in the world and the second most common cause of cancer...
Background: Overexpression of the transmembrane sialomucin podocalyxin, which is known to play a rol...
The molecular heterogeneity of breast cancers makes them very challenging to diagnose and treat. Whi...
The glycocalyx component and sialomucin podocalyxin (PODXL) is required for normal tissue developmen...
Introduction: Podocalyxin (gene name PODXL) is a CD34-related sialomucin implicated...
Abstract Background Overexpression of the transmembra...
Podocalyxin (PODXL), a glycosylated cell surface sialomucin of the CD34 family, is normally expresse...
Podocalyxin (PODXL) is a highly glycosylated and sialylated transmembrane protein that is up-regulat...
Pancreatic invasive ductal adenocarcinoma (PDAC) is a representative intractable malignancy under th...
Oral cancers constitute approximately 2% of all cancers, with the most common histological type bein...
Podocalyxin (PODXL) is a highly glycosylated and sialylated transmembrane protein that is up-regulat...
Lymphatic invasion (LVI), the presence of tumour emboli within the peritumoural lymphatics of the br...
Podocalyxin (PODXL) is a type I membrane sialomucin, originally described in the epithelial cells (p...
23 p.-4 fig.-1 fig.supl.Podocalyxin (PODXL) is a type I membrane sialomucin, originally described in...
The advent of targeted therapies has vastly improved cancer diagnostics and treatments over the last...
Colon cancer is the third most common cancer in the world and the second most common cause of cancer...
Background: Overexpression of the transmembrane sialomucin podocalyxin, which is known to play a rol...
The molecular heterogeneity of breast cancers makes them very challenging to diagnose and treat. Whi...
The glycocalyx component and sialomucin podocalyxin (PODXL) is required for normal tissue developmen...
Introduction: Podocalyxin (gene name PODXL) is a CD34-related sialomucin implicated...
Abstract Background Overexpression of the transmembra...
Podocalyxin (PODXL), a glycosylated cell surface sialomucin of the CD34 family, is normally expresse...
Podocalyxin (PODXL) is a highly glycosylated and sialylated transmembrane protein that is up-regulat...
Pancreatic invasive ductal adenocarcinoma (PDAC) is a representative intractable malignancy under th...
Oral cancers constitute approximately 2% of all cancers, with the most common histological type bein...
Podocalyxin (PODXL) is a highly glycosylated and sialylated transmembrane protein that is up-regulat...
Lymphatic invasion (LVI), the presence of tumour emboli within the peritumoural lymphatics of the br...
Podocalyxin (PODXL) is a type I membrane sialomucin, originally described in the epithelial cells (p...
23 p.-4 fig.-1 fig.supl.Podocalyxin (PODXL) is a type I membrane sialomucin, originally described in...
The advent of targeted therapies has vastly improved cancer diagnostics and treatments over the last...
Colon cancer is the third most common cancer in the world and the second most common cause of cancer...
Background: Overexpression of the transmembrane sialomucin podocalyxin, which is known to play a rol...